The potential of genetic immunization has been acknowledged for almost a decade, but disappointing immunogenicity in humans has delayed its introduction into the clinical arena. To try to increase the potency of genetic immunization, we and others have evaluated 'translocatory' proteins, which are thought to exit living cells by an uncharacterized pathway, and enter neighboring cells in an energy-independent manner. Several laboratories, including our own, have begun to question these remarkable properties. Our previous studies showed that the ability of an epitope to induce major histocompatibility complex (MHC) class I restricted CD8 þ T cells was, indeed, enhanced by its being attached to the proposed translocatory sequence of the HIV-1 tat protein. However, we found little evidence that the increased immunogenicity resulted from transfer of the fusion peptide between living cells, and we proposed that it resulted instead from an increased epitope/MHC expression on the surface of transfected cells. Here, we directly test this hypothesis. We show that cells cotransfected with plasmids encoding an epitope, and the relevant MHC class I allele, can stimulate epitope-specific T cells, and that attachment of the epitope to a putative translocatory sequence -which we term herein an 'integral cationic region' (ICR) -leads to a marked increase in stimulatory activity. This elevated stimulatory capacity does not result from a nonspecific increase in MHC class I expression. We use a high-affinity T-cell receptor (TcR) specific for the epitope/MHC combination to quantitate directly the cell-surface expression of the immunogenic complex, and we show that the attachment of the tat ICR to an epitope results in a substantial enhancement of its cellsurface presentation. These data suggest an alternative explanation for the immune enhancement seen with ICRs.
Introduction
Genetic immunization, first demonstrated some 10 years ago, 1 has evolved from an interesting experimental phenomenon into an approach considered worthy of several clinical trials. [2] [3] [4] [5] [6] However, in contrast to its success in small animal models, where it is effective against viral infections or tumors, the outcome of DNA vaccination in humans has been somewhat disappointing; although responses can be detected, they are (so far) not vigorous. 7, 8 Therefore, to establish DNA vaccination as a major addition to medical care, it is crucial to find ways to enhance its efficacy. CD8 þ T cells play an important part in immunity against virus infections and tumors, and one factor that regulates the ability of any vaccine to induce these cells is the effectiveness of major histocompatibility complex (MHC) class I presentation of antigenic epitopes on the cell surface of antigen-presenting cells (APCs). Effective antigen presentation is, in turn, determined by several factors, including (i) the number of APCs expressing the epitopes and (ii) the number of epitope/MHC complexes on the surface of individual APCs. Epitopes encoded by a DNA vaccine are thought to access the MHC class I pathway of APCs in either of two ways: first, by uptake of DNA by the APC, and endogenous expression of the plasmid-encoded protein; or, second, by cross-priming, a process in which proteins synthesized in other cells are internalized by APCs. Therefore, the number of APCs that express a plasmid-encoded antigen might be increased either by targeting DNA to APCs, or by increasing the effectiveness of cross-priming. Several laboratories have attempted the latter, by taking advantage of oligopeptides that appear to cross cellular membranes, and to transport covalently linked proteins into cells. Such sequences, termed 'protein transduction domains' (PTDs), have been identified in the human immunodeficiency virus (HIV) tat protein, the herpes simplex virus (HSV) VP22 protein, the Drosophila melanogaster homeoproteins, and elsewhere (reviewed in Lindgren et al 9 and Prochiantz 10 ). These sequences have been successfully used as immunoadjuvants in several models, [11] [12] [13] [14] and it has been postulated that the immune enhancement results from the improved delivery of these translocatory proteins to APCs. We have found that fusion of the HIV-1 tat PTD to an epitope enhanced its ability to stimulate CD8 þ T cells in vitro and in vivo, and improved antiviral protection when administered as a plasmid vaccine. 15 However, contrary to our expectations, cell to cell transfer of the fusion peptide contributed little to the enhanced immune stimulation, 15 and in subsequent studies we showed that the HIV tat PTD was unable to direct intercellular transfer of fulllength proteins. 16 As a result, we have questioned whether these supposedly translocatory proteins are, in fact, capable of such unusual maneuvers; 16, 17 and our studies, along with those of other groups, [18] [19] [20] [21] indicate that many of the published claims of intercellular transfer are based on a fixation artifact. Therefore, the term 'protein transduction domain' appears to be a misnomer, and we shall not use it hereinafter. A feature common to all of these sequences is a high content of basic amino acids (lysine and arginine), which confers a strongly positive charge at physiological pH. We have argued that the cationic nature of these residues is central to their biological properties, 16, 17 and we have suggested that these sequences would be better termed 'integral cationic regions' (ICRs). 17 Our previous observations 15, 16 led us to suggest an alternative explanation for the adjuvant effect of the HIV ICR; we proposed that it improved the expression of epitope/MHC complexes on the surface of transfected cells. However, we were unable to directly test this hypothesis, because no reagent was available that would specifically and quantitatively detect these complexes. The ideal reagent for this purpose would be a T-cell receptor (TcR) specific for the epitope/MHC combination; but TcRs are of much lower affinity than antibodies, preventing their stable binding to the epitope/MHC on the cell surface. There are several reasons for the in vivo 'affinity ceiling' of TcRs, but it is clear that the limitation is imposed more by in vivo functional constraints 22 than by structural limitations. Consistent with this, in vitro mutagenesis has allowed a high-affinity TcR to be developed, which retains its specificity for the appropriate epitope/MHC combination. 23, 24 The TcR in question is a modified form of the 2C TcR, which recognizes an epitope termed QL9; this nine amino-acid peptide is derived from the mouse enzyme 2-oxoglutarate dehydrogenase, and is presented by the MHC class I allele H-2 L d . 25 Here, we have used this high-affinity TcR to measure directly the effect of the HIV tat ICR on the cellsurface expression of QL9/L d complexes. We demonstrate that the cell-surface expression of this epitope/ MHC complex is markedly increased when the epitope is expressed within the cell as an ICR fusion product. The effect is specific for the ICR-linked epitope, because overall expression of MHC class I is not increased. ). Therefore, in the cotransfection system, we confirm our previous observation that the presence of an ICR enhances the ability of transfected cells to stimulate CD8 þ T cells. (Figure 2a) . As a positive control, cells were treated with interferon-g (IFNg), which led to an Bfive-fold increase in fluorescence intensity; statistical comparisons of the four groups indicated that only the group treated with IFNg was different from the others (Po0.001). Since our main interest was in the enhanced antigen presentation conferred by the ICR following intracellular synthesis from plasmid DNA, we also measured the L d levels in cells 24 h after transfection of various plasmids ( Figure  2b ). There was no statistically significant difference in L d levels in cells that expressed the NP 118 epitope alone, compared to cells that expressed an ICR-linked epitope (P¼0.18), indicating that the enhanced stimulatory activity shown in Figure 1 is not due to an overall increase in L d expression on the surface of cells that express an ICR. Cells were also stained for the MHC class I H-2 K d allele, which cannot present the NP 118 epitope, and similar results were found (data not shown). Thus, an ICR, whether added exogenously or expressed endogenously, does not lead to a nonspecific increase in MHC class I expression.
Results

Cotransfection
Detection of L d /QL9 complexes on the surface of transfected cells
The data in Figure 1 show that transfected APCs can stimulate T cells in an antigen-specific manner. This readout, although probably the most biologically relevant measure of epitope presentation on APCs, provides no information about the number of APCs that are presenting the epitope, nor does it allow quantitation of epitope/MHC complexes on the APC surface. To address these important issues, we wished to use a highaffinity TcR to detect and quantitate the expression of epitope/MHC complexes on the cell surface. No such TcR is available for epitopes in the LCMV model system, so we instead focused on the QL9 epitope, which is presented by the H-2L d MHC class I allele. 25 A highaffinity TcR specific for the trimolecular complex of b2-microglobulin, L d , and the QL9 peptide has recently been developed, 23, 24 and we first determined whether this reagent could identify its target on the surface of transfected cells. HeLa cells were transfected with pCMV-L d , incubated for 24 h, and coated with the QL9 peptide. After 1 h, the cells were washed and stained using the high-affinity TcR as described in Materials and methods; a diagram of the detection system is shown in Figure 3a . When viewed by fluorescence microscopy (Figure 3b ), a proportion of these cells fluoresced very strongly, indicating successful L d transfection and expression, which, in turn, permitted presentation of the QL9 peptide. No fluorescence was detected in nontransfected cells or in cells that had not been coated with the QL9 peptide (not shown).
Fusion to the HIV tat ICR increases QL9 epitope presentation
Having shown that the enhanced immune stimulation by ICR-linked T-cell epitopes in a DNA vaccine (Figure 1) was not due to an overall increase in MHC class I surface expression (Figure 2 In all cases, a transfection efficiency of B25% was confirmed by staining for MHC class I molecules (not shown). The cells were incubated for 24 h at 371C in complete DMEM medium, then were stained using the soluble TcR method, and analyzed by flow cytometry, which allowed the enumeration of epitope-presenting cells and the semiquantitative measurement of expression levels on positive cells. As shown in Figure 4a , only background signal was noted for cells cotransfected with pCMV. Cells cotransfected with pCMV-QL9 had a clear 'shoulder' (Figure 4b ), consistent with low levels of epitope presentation on the cells that had been successfully cotransfected. Strikingly, cells that had been cotransfected with pCMV-ICR-QL9 showed a much higher mean signal intensity (Figure 4c ), indicating that fusion of the QL9 epitope to the ICR resulted in markedly enhanced epitope presentation by individual APCs.
Attachment of an ICR does not target proteins to the cell surface
The above result raised the possibility that an ICR might somehow direct contiguous MHC molecules to the cell surface. To investigate whether or not the effect could be reproduced by linking the MHC molecule (rather than the epitope) to an ICR, a plasmid was prepared containing the ICR open reading frame (ORF) linked in-frame to the ORF of the L d molecule. After transfection, cells were Epitope presentation by MHC class I JA Leifert et al incubated for 24 h at 371C in complete medium (DMEM). We evaluated the number of cells that expressed L d , and found it to be essentially identical (B20%) whether or not the L d protein was attached to the HIV tat ICR (Figure 5a ), confirming our previous finding that the HIV tat ICR cannot direct intercellular transfer of a biologically active protein between living cells. 16, 17 Most relevant to the present study, the quantity of L d expressed at the surface of transfected cells is indistinguishable (Figure 5b) , suggesting that the attachment of an ICR to a protein does not invariably increase its delivery to the cell surface.
Discussion
In recent years, 'protein transduction domains' have become increasingly popular as potential adjuvants for Epitope presentation by MHC class I JA Leifert et al immunization, and most studies suggest that these sequences can, indeed, enhance the immune response (in particular, the CD8 þ T-cell response) against viral infections or tumors. Current dogma insists that these sequences (and the proteins from which they come) can move between living cells, exiting cells by an uncharacterized pathway, and entering cells in a manner independent of receptors, transporters, or adsorptive endocytosis; indeed, cellular uptake is said to occur efficiently at 41C. 26, 27 It has been suggested that such intercellular transfer can result in 100% of tissue culture cells eventually containing the translocatory proteins. For this reason, the immunostimulatory effect of these sequences, when attached to antigens, has been attributed to the extensive spread of the fusion proteins, resulting in improved antigen presentation via crosspriming and, consequently, a stronger immune response. Although this hypothesis is attractive, several observations indicated that the immune enhancement might be unrelated to the apparent translocatory functions. For example, a VP22 deletion mutant that lacked translocatory activity was, nevertheless, able to increase the immunogenicity of an attached antigen, 28 and VP22 alone appeared to increase tumor immunity, 12 suggesting the possibility that this viral protein might have a nonspecific adjuvant effect.
Furthermore, the translocatory efficiency of these proteins, and the related ICRs, has recently come into question. The HSV VP22 protein can adhere very rapidly to the nuclei of methanol-fixed cells, 20, 21 and there is no doubt that this phenomenon can lead to an artifact whereby, during the process of organic fixation, VP22 (and any proteins attached thereto) can be released from a cell in which it has been synthesized, and can immediately adhere to other nonexpressing cells. 18, 19 Many claims that these translocatory proteins can efficiently enter cells in culture are based on this fixation artifact. This artifact is not restricted to VP22; we have shown that it occurs also in cells expressing the HIV tat 'ICR', 16 and others have shown that the Drosophiladerived sequence also is open to artifact. 29 In additionand of particular importance for gene therapy and vaccine studies in which these proteins are vector-borne and therefore are synthesized in vivo -it is extremely difficult to demonstrate transfer of these so-called 'ferry proteins' between living cells. 15, 16, [18] [19] [20] [21] 30, 31 We have recently reviewed the phenomenon of translocatory proteins and PTDs, and have argued that many of the biological effects attributed to these highly basic sequences result not from an intrinsic translocatory property, but instead from their release from dead or dying cells, their rapid and avid electrostatic attachment to cell-surface polyanions such as heparans, and their subsequent uptake by endocytosis. 17 Nevertheless, several studies 12,13,28,32 -including one from this laboratory 15 -have reported that immune enhancement results from the attachment of these sequences to antigenic moieties. How might this enhancement be effected, if not by transfer between living cells? There are a number of alternatives, in addition to the possible limited transfer from dead cells to living cells described above: for example, fusion to VP22 may increase the steady-state level of an antigenic protein, 28 which could increase its immunogenicity; or the highly basic sequences alone may have some adjuvant effect, as has been shown for poly-L-arginine. 33 In this study, we show that the HIV tat ICR can enhance the stimulatory capacity of cotransfected cells (Figure 1) , and that this increase does not result from a nonspecific increase in MHC class I expression (Figure 2 ), suggesting that it is specific to the ICR-linked epitope/MHC complex. Using a high-affinity TcR 24 to quantitate antigen presentation, we conclude that the direct linkage of an ICR to a T-cell epitope results in an enhanced epitope presentation on the cell surface (Figure 4) . The molecular interactions that lead to this unexpected outcome remain obscure and are under investigation. However, covalent attachment of the HIV tat ICR to the L d molecule does not alter its cell-surface expression (Figure 5b) , indicating that the effect of the ICR is unlikely to be mediated by increased trafficking to the cell membrane. No cell-to-cell transfer of ICR-L d molecules was observed (Figure 5a ), supporting our previous findings that translocation of ICR-linked molecules from transfected live cells into nontransfected live cells is minimal. 15, 16 The increased presentation of the QL9 epitope on the cell surface, revealed using the high-affinity TcR (Figure 4 ), correlates well with the enhanced immune stimulatory capacity of cells transfected with pCMV-ICR-NP 118 ( Figure  1 ). At least two explanations for the increased stimulation can be proposed. First, it is clear that the population of cells transfected with a plasmid encoding the ICR epitope contains many individual cells that express much higher levels of epitope/L d than are seen in cells transfected with a plasmid encoding the epitope alone (Figure 4 , compare b and c); perhaps these 'high expressers' are better able to stimulate the epitope-specific CD8 þ T cells. However, it is known that relatively low levels of epitope/MHC complex are sufficient to stimulate activated CD8 þ T cells, and one might argue that, if a cell has enough epitope to stimulate CD8 þ T cells, any increase in the epitope concentration might be biologically meaningless. Therefore, we favor a second hypothesis: it is possible that the population of cells transfected with pCMV-QL9 contains some cells that express the L d /QL9 complex at a level too low to stimulate CD8 þ T-cell responses; but the effect of the ICR sequence might increase the level of QL9/L d expression in such cells above this critical threshold, rendering those cells capable of stimulating CD8 þ T cells. In this case, even if the total number of QL9-expressing cells was the same in the two transfected populations, the number of effective antigenpresenting cells would be greater in the population of cells transfected with the ICR-epitope plasmid. This increase in number would result not from intercellular transfer of ICRlinked epitope, but instead from the ICR-driven transition of some cells from subthreshold levels of epitope presentation, to suprathreshold levels.
In conclusion, addition of ICR to a DNA minigene plasmid results in an increased presentation of the epitope on the cell surface, by a mechanism that remains to be determined. Therefore, ICR sequences, even if not capable of unconventional cell exit and entry, still may be useful tools for in vitro transfections and in vivo immunizations. 
Materials and methods
Cell lines
HeLa cells were maintained in DMEM medium, and Balb clone 7 cells ((Balb cl7); a fibroblast cell line from BALB/c mice) were maintained in RPMI medium (Sigma, St Louis, MO, USA), each supplemented with 10% fetal calf serum (FCS), L-glutamine, and penicillinstreptomycin ('complete medium'). Cells were grown at 371C in 5% CO 2 .
Synthetic peptides
Peptides were purchased from PeptidoGenic Inc. (Livermore, CA, USA), having been purified to 98% by highperformance liquid chromatography. The peptides were QL9 (QLSPFPFDL), NP 118 (RPQASGVYM), and ICR-NP 118 (YGRKKRRQRRRRPQASGVYM).
DNA constructs
An ORF encoding the integral cationic domain (ICR) from the HIV-1 tat protein was cloned into the Not I site of pCMV (Clontech, Palo Alto, CA, USA), to generate the plasmid vector pCMV-ICR containing a 'Kozak' sequence flanking the ATG translational initiation codon. 34 The CD8 þ T-cell epitope NP 118 from the nucleoprotein (NP) of LCMV was inserted into pCMV and pCMV-ICR to generate pCMV-NP 118 and pCMV-ICR-NP 118 as previously described. 15 In a similar manner, the sequence coding for QL9 was inserted into pCMV and pCMV-ICR to generate pCMV-QL9 and pCMV-ICR-QL9 respectively. MHC class I H2-L d containing plasmids were generated by introducing a multiple cloning site into pCMV to generate pCMV-JAL. 
Preparation of soluble TcR
Soluble high-affinity TcR was produced from insect cells as described previously. 35, 36 Briefly, the pRMHa-3 Drosophila expression plasmids containing the wild-type 2Cb and the mutant 2Ca chain called m6a (m6a CDR3 sequence HQGRY was substituted for the 2Ca CDR3 sequence GFASA), with deleted transmembrane regions, were cotransfected together with a plasmid conferring G418 resistance (pUChsNEO) into SC2 D. melanogaster cells by Ca 3 (PO 4 ) 2 precipitation (19:19:1 ratio a:b:NEO). Stable transfectants were selected and maintained at 271C in Schneider's complete media (Gibco) containing 1 mg/ml G418. TCR expression was induced by the addition of CuSO 4 to a final concentration of 500 mM. Supernatants containing the m6a TCR, harvested after 4 days and stored at 41C, were used directly to detect QL9/L d .
In vitro transfections and loading of stimulator cells with peptide
Cells were transfected using the Lipofectamine PLUS kit (Life Technologies Inc., Gaithersburg, MD, USA) according to the manufacturer's recommendations. Cells were incubated in OPTI-MEM I medium (Life Technologies) for 3 h. The transfection medium was then replaced by complete DMEM medium (for HeLa cells) or RPMI medium (for Balb cl7 cells). When soluble peptide was used to load stimulator cells, the cells were incubated with 10 À6 M peptide in complete medium for 1 h at 371C.
Staining of cells with TCR
After transfection, or peptide loading, cells were washed in 1% BSA/PBS and incubated with the QL9-specific high-affinity TCR for 30 min. Cells were again washed and stained with biotinylated anti-Vb8 antibody (F23.1, BD Pharmingen, San Diego, CA, USA). After another washing step, fluorochrome-labeled streptavidin was added as the last step of the staining procedure prior to washing, fixation (2% formalin/PBS) and FACS analysis (Streptavidin-PE, Pharmingen) or fluorescent microscopy (Streptavidin-Rhodamine Red-XTM, Jackson Immuno Research, West Grove, PA, USA).
Intracellular cytokine staining
Peripheral blood lymphocytes or spleen cells from previously infected mice were cultured at 371C, 5% CO 2 for 6 h in the presence of the LCMV CD8 þ T cell peptide epitope NP 118 in RPMI containing 10% FCS, L-glutamine, and penicillin-streptomycin. Brefeldin A (Sigma, St Louis, MO, USA) was added at a final concentration of 5 mg/ml to inhibit secretion of cytokines. Cells were washed and stained for CD8 using cychromelabeled anti-CD8 antibodies (Caltag Laboratories, Burlingame, CA, USA) in round-bottomed 96-well plates. The cells were washed and permeabilized using Perm/ Wash buffer (Pharmingen), then stained for intracellular interferon-g with FITC-labeled antibodies (Pharmingen, San Diego, CA, USA). Samples were washed and resuspended in phosphate-buffered saline (PBS) containing 2% formalin. Cells were acquired on a FACScan flow cytometer and analyzed using CellQuest software (Becton Dickinson, San Jose, CA, USA).
